Penumbra (0P8) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0P8 Analyst Ratings

Hold

1 Buy

4 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Penumbra

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0P8 Stock 12 Month Forecast

Average Price Target

€316.86

▲(12.20% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is €316.86 with a high forecast of €327.91 and a low forecast of €293.72. The average price target represents a 12.20% change from the last price of €282.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"195":"€195","328":"€328","228.25":"€228.3","261.5":"€261.5","294.75":"€294.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":327.91197252,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€327.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":316.86467077200007,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€316.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":293.7179433,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€293.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[195,228.25,261.5,294.75,328],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,278,281.83938250153847,285.67876500307693,289.5181475046154,293.35753000615387,297.19691250769233,301.0362950092308,304.8756775107692,308.7150600123077,312.55444251384614,316.3938250153846,320.2332075169231,324.07259001846154,{"y":327.91197252,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,278,280.9895900593846,283.97918011876925,286.9687701781539,289.9583602375385,292.9479502969231,295.93754035630775,298.9271304156923,301.91672047507694,304.90631053446157,307.8959005938462,310.8854906532308,313.87508071261544,{"y":316.86467077200007,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,278,279.20907256153845,280.4181451230769,281.6272176846154,282.83629024615385,284.0453628076923,285.25443536923075,286.46350793076925,287.6725804923077,288.88165305384615,290.0907256153846,291.2997981769231,292.50887073846155,{"y":293.7179433,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":212.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€327.91

Average Price Target€316.86

Lowest Price Target€293.72

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

€327.91

Hold

16.12%

Upside

Reiterated

06/12/26

Wells Fargo Reaffirms Their Hold Rating on Penumbra (PEN)

Shagun Singh Chadha

RBC Capital

€327.91

Hold

16.12%

Upside

Reiterated

06/11/26

Penumbra (PEN) Gets a Hold from RBC Capital

William Plovanic

Canaccord Genuity

€327.91

Hold

16.12%

Upside

Reiterated

06/02/26

Canaccord Genuity Reaffirms Their Hold Rating on Penumbra (PEN)

Vijay Kumar

Evercore ISI

€302.49→€293.72

Buy

4.01%

Upside

Reiterated

05/07/26

Penumbra price target lowered to $335 from $345 at Evercore ISIPenumbra price target lowered to $335 from $345 at Evercore ISI

Joanne Wuensch

Citi

€327.91→€306.87

Hold

8.66%

Upside

Reiterated

05/07/26

Penumbra price target lowered to $350 from $374 at CitiPenumbra price target lowered to $350 from $374 at Citi

Michael Matson

Needham

―

Hold

―

Reiterated

02/25/26

Hold Rating Maintained on Penumbra Amid Strong Results but Limited Visibility Ahead of Boston Scientific Acquisition

Ryan Zimmerman

BTIG

―

Hold

―

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Penumbra (NYSE: PEN), Orchestra BioMed Holdings (NASDAQ: OBIO) and Teladoc (NYSE: TDOC)

Priya Sachdeva

UBS

€293.72→€327.91

Hold

16.12%

Upside

Downgraded

01/20/26

UBS downgrades Penumbra (PEN) to a Hold

Brandon Vazquez

William Blair

―

Hold

―

Downgraded

01/17/26

Penumbra downgraded to Market Perform from Outperform at William BlairPenumbra downgraded to Market Perform from Outperform at William Blair

Richard Newitter

Truist Financial

€324.4→€327.91

Hold

16.12%

Upside

Downgraded

01/16/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Atea Pharmaceuticals (NASDAQ: AVIR) and Penumbra (NYSE: PEN)

Mike Kratky

Leerink Partners

€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Penumbra downgraded to Market Perform from Outperform at LeerinkPenumbra downgraded to Market Perform from Outperform at Leerink

David Rescott

Robert W. Baird

€302.49→€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Robert W. Baird downgrades Penumbra (PEN) to a Hold

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

01/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew O'Brien

Piper Sandler

€289.33→€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Penumbra downgraded to Neutral from Overweight at Piper SandlerPenumbra downgraded to Neutral from Overweight at Piper Sandler

Robbie Marcus

J.P. Morgan

€241.11→€324.4

Buy

14.87%

Upside

Upgraded

12/18/25

Penumbra: Accelerating Growth, Margin Upside, and 2026+ Catalysts Support Overweight (Buy) Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

€327.91

Hold

16.12%

Upside

Reiterated

06/12/26

Wells Fargo Reaffirms Their Hold Rating on Penumbra (PEN)

Shagun Singh Chadha

RBC Capital

€327.91

Hold

16.12%

Upside

Reiterated

06/11/26

Penumbra (PEN) Gets a Hold from RBC Capital

William Plovanic

Canaccord Genuity

€327.91

Hold

16.12%

Upside

Reiterated

06/02/26

Canaccord Genuity Reaffirms Their Hold Rating on Penumbra (PEN)

Vijay Kumar

Evercore ISI

€302.49→€293.72

Buy

4.01%

Upside

Reiterated

05/07/26

Penumbra price target lowered to $335 from $345 at Evercore ISIPenumbra price target lowered to $335 from $345 at Evercore ISI

Joanne Wuensch

Citi

€327.91→€306.87

Hold

8.66%

Upside

Reiterated

05/07/26

Penumbra price target lowered to $350 from $374 at CitiPenumbra price target lowered to $350 from $374 at Citi

Michael Matson

Needham

―

Hold

―

Reiterated

02/25/26

Hold Rating Maintained on Penumbra Amid Strong Results but Limited Visibility Ahead of Boston Scientific Acquisition

Ryan Zimmerman

BTIG

―

Hold

―

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Penumbra (NYSE: PEN), Orchestra BioMed Holdings (NASDAQ: OBIO) and Teladoc (NYSE: TDOC)

Priya Sachdeva

UBS

€293.72→€327.91

Hold

16.12%

Upside

Downgraded

01/20/26

UBS downgrades Penumbra (PEN) to a Hold

Brandon Vazquez

William Blair

―

Hold

―

Downgraded

01/17/26

Penumbra downgraded to Market Perform from Outperform at William BlairPenumbra downgraded to Market Perform from Outperform at William Blair

Richard Newitter

Truist Financial

€324.4→€327.91

Hold

16.12%

Upside

Downgraded

01/16/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Atea Pharmaceuticals (NASDAQ: AVIR) and Penumbra (NYSE: PEN)

Mike Kratky

Leerink Partners

€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Penumbra downgraded to Market Perform from Outperform at LeerinkPenumbra downgraded to Market Perform from Outperform at Leerink

David Rescott

Robert W. Baird

€302.49→€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Robert W. Baird downgrades Penumbra (PEN) to a Hold

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

01/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew O'Brien

Piper Sandler

€289.33→€327.91

Hold

16.12%

Upside

Downgraded

01/15/26

Penumbra downgraded to Neutral from Overweight at Piper SandlerPenumbra downgraded to Neutral from Overweight at Piper Sandler

Robbie Marcus

J.P. Morgan

€241.11→€324.4

Buy

14.87%

Upside

Upgraded

12/18/25

Penumbra: Accelerating Growth, Margin Upside, and 2026+ Catalysts Support Overweight (Buy) Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

3 Months

Travis SteedBank of America Securities

Success Rate

6/8 ratings generated profit

Average Return

+14.80%

Copying Travis Steed's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +14.80% per trade.

1 Year

Travis SteedBank of America Securities

Success Rate

8/8 ratings generated profit

Average Return

+18.70%

Copying Travis Steed's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.70% per trade.

2 Years

Travis SteedBank of America Securities

Success Rate

8/8 ratings generated profit

Average Return

+17.16%

Copying Travis Steed's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +17.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0P8 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0P8 has received 1 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0P8 average Analyst price target in the past 3 months is 316.86.

Each month's total comprises the sum of three months' worth of ratings.

0P8 Financial Forecast

0P8 Earnings Forecast

Next quarter’s earnings estimate for 0P8 is €1.01 with a range of €0.92 to €1.06. The previous quarter’s EPS was €0.72. 0P8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0P8 has Performed in-line its overall industry.

0P8 Sales Forecast

Next quarter’s sales forecast for 0P8 is €340.48M with a range of €333.02M to €346.68M. The previous quarter’s sales results were €327.50M. 0P8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0P8 has Performed in-line its overall industry.

0P8 Stock Forecast FAQ

What is DE:0P8’s average 12-month price target, according to analysts?

Based on analyst ratings, Penumbra Inc.’s 12-month average price target is 316.86.

What is DE:0P8’s upside potential, based on the analysts’ average price target?

Penumbra Inc. has 12.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Penumbra Inc. a Buy, Sell or Hold?

Penumbra Inc. has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.

What is Penumbra Inc.’s share price target?

The average share price target for Penumbra Inc. is 316.86. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €327.91 ,and the lowest forecast is €293.72. The average share price target represents 12.20% Increase from the current price of €282.4.

What do analysts say about Penumbra Inc.?

Penumbra Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Penumbra Inc.?

To buy shares of DE:0P8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Penumbra (0P8) Stock Forecast & Price Target

0P8 Analyst Ratings

0P8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Penumbra

0P8 Analyst Recommendation Trends

0P8 Financial Forecast

0P8 Earnings Forecast

0P8 Sales Forecast

0P8 Stock Forecast FAQ

Detailed List of Analyst Forecasts